nach oben

Erschienen in:

04.08.2021 | Original Article

Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience

verfasst von: Barbara Loteta, Annalisa Paviglianiti, Virginia Naso, Anna Ferreri, Tiziana Moscato, Giuseppe Console, Filippo Antonio Canale, Giuseppe Irrera, Marta Pugliese, Antonella Di Costanzo, Pasquale Fabio Provenzano, Viviana Loddo, Gaetana Porto, Giuseppa Cusumano, Letteria Russo, Nicola Meliambro, Valentina Romeo, Domenico Porcino, Salvatore Gallo, Tiziana Gangemi, Antonio Maria Rossetti, Massimo Martino

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent adverse events compromising quality of life (QoL) in patients undergoing autologous stem cell transplantation (ASCT). However, CINV prophylaxis is still lacking uniformity for high-dose melphalan (HDM), which is used to condition patients with multiple myeloma (MM). Netupitant/palonosetron (NEPA) is administered with dexamethasone (DEXA) for CINV prevention in several chemotherapy regimens. Our study aims to assess the efficacy of NEPA, without DEXA, in preventing CINV in 106 adult patients with MM receiving HDM and ASCT. All patients had antiemetic prophylaxis with multiple doses of NEPA 1 h before the start of conditioning and after 72 h and 120 h. A complete response (CR) was observed in 99 (93%) patients at 120 h (overall phase). The percentage of patients with complete control was 93%. The CR rate during the acute phase was 94% (n = 100). During the delayed phase, the CR rate was 95% (n = 101). Grade 1 nausea and vomiting were experienced by 82% and 12% of the patients, respectively. Grade 2 nausea was reported in 18% and vomiting in 10% of patients. Our results showed, for the first time, that NEPA, without DEXA, was a well-tolerated and effective antiemetic option for MM patients receiving HDM followed by ASCT.

Nur mit Berechtigung zugänglich

Aapro M, Ruffo P, Panteri R, Costa S, Piovesana V (2018) Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey. Cancer Rep (Hoboken) 1:e1127CrossRef

Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328–1333CrossRef

Apolito V, Giaccone L, Ferrero S, Larocca A, Cavallo F, Coscia M, Beggiato E, Butera S, Martella F, Dainese C, Cetani G, Scaldaferri M, Cattel F, Boccadoro M, Ferrero D, Bruno B, Cerrano M (2020) Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. Ann Hematol 99:2197–2199CrossRef

Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO (2013) Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 19:344–356CrossRef

Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr, Jaglowski S, Penza S, Andritsos LA, Devine SM (2014) Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. Support Care Cancer 22:2911–2916CrossRef

Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ, Medical Research Council Adult Leukaemia Working P (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883CrossRef

Clark SM, Clemmons AB, Schaack L, Garren J, DeRemer DL, Kota VK (2016) Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. J Oncol Pharm Pract 22:416–422CrossRef

D’Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM (2020) Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant 26:e177–e182CrossRef

Deauna-Limayo D, Aljitawi OS, Ganguly S, Abhyankar S, Wick JA, McGuirk JP (2014) Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: a pilot study. J Oncol Pharm Pract 20:263–269CrossRef

10.

Decramer M, Lacquet LM, Fagard R, Rogiers P (1994) Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 150:11–16CrossRef

11.

Del Gaudio N, Di Costanzo A, Liu NQ, Conte L, Migliaccio A, Vermeulen M, Martens JHA, Stunnenberg HG, Nebbioso A, Altucci L (2019) BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition. Cell Death Dis 10:338CrossRef

12.

Di Costanzo A, Del Gaudio N, Conte L, Dell’Aversana C, Vermeulen M, de The H, Migliaccio A, Nebbioso A, Altucci L (2018) The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia. Oncogene 37:2559–2572CrossRef

13.

Di Costanzo A, Troiano A, di Martino O, Cacace A, Natale CF, Ventre M, Netti P, Caserta S, Pollice A, La Mantia G, Calabro V (2012) The p63 protein isoform DeltaNp63alpha modulates Y-box binding protein 1 in its subcellular distribution and regulation of cell survival and motility genes. J Biol Chem 287:30170–30180CrossRef

14.

Di Renzo N, Musso M, Scime R, Cupri A, Perrone T, De Risi C, Pastore D, Guarini A, Mengarelli A, Benedetti F, Mazza P, Capria V, Chiusolo P, Cupelli L, Federico V, Bozzoli V, Messa AR, Codega P, Bonizzoni E, Specchia G (2020) Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study. Bone Marrow Transplant 55:2114–2120CrossRef

15.

Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, Jordan K, Young A, Aapro M (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28:1260–1267CrossRef

16.

Giralt S (2010) 200 mg/m(2) melphalan–the gold standard for multiple myeloma. Nat Rev Clin Oncol 7:490–491CrossRef

17.

Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW (2011) Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol 22:939–946CrossRef

18.

Gonullu G, Demircan S, Demirag MK, Erdem D, Yucel I (2012) Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 20:1435–1439CrossRef

19.

Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla RJ (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340–1346CrossRef

20.

Isoda A, Saito R, Komatsu F, Negishi Y, Oosawa N, Ishikawa T, Miyazawa Y, Matsumoto M, Sawamura M, Manaka A (2017) Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: a phase II study. Int J Hematol 105:478–484CrossRef

21.

Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll HJ (2011) The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant 46:784–789CrossRef

22.

Larsen J, Nordstrom G, Ljungman P, Gardulf A (2004) Symptom occurrence, symptom intensity, and symptom distress in patients undergoing high-dose chemotherapy with stem-cell transplantation. Cancer Nurs 27:55–64CrossRef

23.

Lopez-Jimenez J, Martin-Ballesteros E, Sureda A, Uralburu C, Lorenzo I, del Campo R, Fernandez C, Calbacho M, Garcia-Belmonte D, Fernandez G (2006) Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 91:84–91PubMed

24.

Martino M, Olivieri A, Offidani M, Vigna E, Moscato T, Fedele R, Montanari M, Console G, Gentile M, Messina G, Irrera G, Morabito F (2013) Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opin Investig Drugs 22:619–634CrossRef

25.

Mirabile A, Celio L, Magni M, Bonizzoni E, Gianni AM, Di Nicola M (2014) Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy. Future Oncol 10:2569–2578CrossRef

26.

Musso M, Scalone R, Crescimanno A, Bonanno V, Polizzi V, Porretto F, Bianchini C, Perrone T (2010) Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 45:123–127CrossRef

27.

Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting–two new agents. J Support Oncol 1:89–103PubMed

28.

Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, Dolstra H, Lankester AC, Mohty M, Montoto S, Peffault de Latour R, Snowden JA, Styczynski J, Yakoub-Agha I, Kroger N, European Society for B, Marrow T (2020) The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus. Bone Marrow Transplant 55:1604–1613CrossRef

29.

Pastore D, Bruno B, Carluccio P, De Candia MS, Mammoliti S, Borghero C, Chierichini A, Pavan F, Casini M, Pini M, Nassi L, Greco R, Tambaro FP, Stefanoni P, Console G, Marchesi F, Facchini L, Mussetti A, Cimminiello M, Saglio F, Vincenti D, Falcioni S, Chiusolo P, Olivieri J, Natale A, Faraci M, Cesaro S, Marotta S, Proia A, Donnini I, Caravelli D, Zuffa E, Iori AP, Soncini E, Bozzoli V, Pisapia G, Scalone R, Villani O, Prete A, Ferrari A, Menconi M, Mancini G, Gigli F, Gargiulo G, Bruno B, Patriarca F, Bonifazi F (2020) Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. Ann Hematol 99:867–875CrossRef

30.

Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, Pidduck W, Bushehri A, Chow E, Jerzak KJ (2019) ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer 27:87–95CrossRef

31.

Schakman O, Gilson H, Thissen JP (2008) Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 197:1–10CrossRef

32.

Schmitt T, Goldschmidt H, Neben K, Freiberger A, Husing J, Gronkowski M, Thalheimer M, le Pelzl H, Mikus G, Burhenne J, Ho AD, Egerer G (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32:3413–3420CrossRef

33.

Tendas A, Marchesi F, Mengarelli A, Annibali O, Tomarchio V, Saltarelli D, Chierichini A, Di Venanzio M, Sollazzo F, Piedimonte M, Cupelli L, Bruno A, De Angelis G, Delbono L, Niscola P, Perrotti AP, de Fabritiis P, Arcese W, Rome Transplant N (2019) Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions. Support Care Cancer 27:793–803CrossRef

34.

Tendas A, Niscola P, Perrotti A, Dentamaro T, de Fabritiis P, Arcese W, Rome Transplant Network Quality of Life Working P (2015) Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need. Support Care Cancer 23:2211CrossRef

35.

Tendas A, Sollazzo F, Bruno A, Cupelli L, Niscola P, Pignatelli AC, Dentamaro T, de Fabritiis P, Arcese W (2012) Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant. Support Care Cancer 20:891–892CrossRef

36.

Trifilio S, Welles C, Seeger K, Mehta S, Fishman M, McGowan K, Strejcek K, Eiten E, Pirotte C, Lucier E, DeFrates S, Mehta J (2017) Olanzapine reduces chemotherapy-induced nausea and vomiting compared with aprepitant in myeloma patients receiving high-dose melphalan before stem cell transplantation: a retrospective study. Clin Lymphoma Myeloma Leuk 17:584–589CrossRef

37.

Uchida M, Ikesue H, Miyamoto T, Kato K, Suetsugu K, Ichinose K, Hiraiwa H, Sakurai A, Takenaka K, Muta T, Iwasaki H, Teshima T, Shiratsuchi M, Egashira N, Akashi K, Oishi R (2013) Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation. Biol Pharm Bull 36:819–824CrossRef

Titel: Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience
verfasst von: Barbara Loteta
Annalisa Paviglianiti
Virginia Naso
Anna Ferreri
Tiziana Moscato
Giuseppe Console
Filippo Antonio Canale
Giuseppe Irrera
Marta Pugliese
Antonella Di Costanzo
Pasquale Fabio Provenzano
Viviana Loddo
Gaetana Porto
Giuseppa Cusumano
Letteria Russo
Nicola Meliambro
Valentina Romeo
Domenico Porcino
Salvatore Gallo
Tiziana Gangemi
Antonio Maria Rossetti
Massimo Martino
Publikationsdatum: 04.08.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 1/2022
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-021-06472-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Timing of blood sampling to alleviate chemotherapy contraindications

Correlates of financial toxicity in adult cancer patients and their informal caregivers

Exploring the relationship among dispositional optimism, health-related quality of life, and CIPN severity among colorectal cancer patients with chronic peripheral neuropathy

Illness unpredictability and psychosocial adjustment of adolescent and young adults impacted by parental cancer: the mediating role of unmet needs

Financial toxicity in sarcoma patients and survivors in Germany: results from the multicenter PROSa study

Sleep problems and their interaction with physical activity and fatigue in hematological cancer patients during onset of high dose chemotherapy

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie